Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2022-08-23 Director's Dealing
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-08-23 English
8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the completion of an acquisition (merger) of La Jolla Pharmaceutical Company by Innoviva, Inc., including details about the tender offer, merger agreement, and the resulting corporate structure changes. It also references exhibits related to the merger agreement and press release. This type of filing is specifically related to merger and acquisition activity. The document is not a full annual or quarterly report, nor is it a simple announcement or certification. Therefore, the most appropriate classification is 'M&A Activity' (TAR).
2022-08-22 English
SC TO-T/A Filing
Regulatory Filings
2022-08-22 English
SC TO-T/A Filing
Regulatory Filings
2022-08-16 English
10-Q
Interim / Quarterly Report Q2 2022
2022-07-27 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 27, 2022, by Innoviva, Inc. It reports the issuance of a press release regarding the company's results of operations and financial condition for the quarter ended June 30, 2022. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The text explicitly states that the information is being furnished and is not deemed "filed" for certain regulatory purposes. The length of the document is 3932 characters, which is relatively short and consistent with a regulatory announcement rather than a full financial report. According to the rules, such a document that announces or furnishes a press release about quarterly results without containing the full financial data should be classified as a Regulatory Filing (RNS), as it does not meet the criteria for an Interim/Quarterly Report (IR) or Earnings Release (ER) since it lacks substantive financial data within the text itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-07-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.